An experimental device that offers multiple tunable wavelengths—the TRASER (Total Reflection Amplification of Spontaneous Emission Radiation)—is safe and effective in the treatment of nasal telangiectasias, according to a study published in Lasers in Surgery and Medicine (August 2017).
Paul M. Friedman, MD, et al, treated 15, Fitzpatrick skin type I and II subjects (aged 42–73) for nasal telangiectasias of various sizes. The TRASER was tuned to produce a narrow spectral output peaking at 541 +/- 5nm with 20ms to 40ms pulse widths. Blinded analysis of pre- and post-images (30 days following treatment) and subject self-assessment were used to measure efficacy.
The 13 subjects who completed the study all achieved a 2-point improvement of telangiectasis on the 5-point Telangiectasia Scale and >75% of patients had at least a 75% reduction in blood vessels. The researchers noted that larger vessels required a longer pulse duration (40ms); smaller vessels responded best to shorter pulse durations (25ms), and no serious adverse events were recorded.
